CTI Bites Off Big Chunk Of Myelofibrosis Market With Vonjo Approval
Executive Summary
The accelerated approval for the JAK2/IRAK1 inhibitor, CTI’s first commercial product, carves out an underserved market accounting for about one-third of the US myelofibrosis population.
You may also be interested in...
GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
Keeping Track: US FDA Approves Carvykti, Vonjo, But Turns Down Lenacapavir, Filsuvez And GC1507
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.